|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate the possible mechanism, bioinformatics analysis and mass spectrometry technology was used to determine the most notably changing molecule and signaling pathways, and it was determined and verified that CD38 regulated the metabolic‑associated signaling pathways associated with tumor protein 53, hypoxia inducible factor‑1α and sirtuin 1.
|
30535454 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High coexpression of CD38/CD101 on peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T cells or tumor-infiltrating lymphocytes (TILs) was found to be most significantly correlated with Tumor/Node/Metastasis (T/N/M) classification and clinical stage, in contrast PD-1<sup>+</sup>CD8<sup>+</sup> T cells could not correlate with T classification.
|
30689488 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is increasing evidence that CD38 antibodies also improve host-anti-tumor immune response by eliminating CD38-positive immune suppressor cells, including regulatory T cells, regulatory B cells, and myeloid-derived suppressor cells.
|
30826127 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor extended from T10 to the sacrum, and a conventional operation would have entailed serial laminectomies that would cross the thoracolumbar and lumbosacral junctions, possibly requiring an instrumented fusion.
|
31504844 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, monitoring CD38 expression has gained great attention for tracking the progression of tumors and cancer treatment.
|
31632568 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study indicates that flow cytometry can be used to examine the tumor microenvironment in HL and that percentage of HLA-DR/CD38 copositive lymphocytes may be a biomarker for relapse and refractoriness in pediatric HL.
|
30009533 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, CD38 expression in tumor tissues was verified by histological analysis.
|
29450576 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is increasing evidence that CD38 antibodies also improve host-anti-tumor immune response by eliminating CD38-positive immune suppressor cells, including regulatory T cells, regulatory B cells, and myeloid-derived suppressor cells.
|
29702148 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
|
29500635 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lastly, blocking CD38 expression improved tumor control even when using Th0 anti-tumor T cells.
|
29129787 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the present study, we found that in wild-type and ARH1-deficient mice deletion of the CD38 gene reduced tumor formation.
|
29228209 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that <sup>64</sup>Cu-DOTA-Dara can efficiently bind CD38 on the surface of MM cells and was mainly detected in the bones associated with tumor in a MM murine model.
|
29301755 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Large data sets of human tumors reveal expression of CD38 in a subset of tumors with high levels of basal or treatment-induced T-cell infiltration, where immune checkpoint therapies are thought to be most effective.
|
30012853 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrates a novel connection between CD38, modulation of NAD<sup>+</sup>, and tumor cell metabolism in prostate cancer.
|
30076241 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The production of extracellular adenosine is mediated by the cell surface ectoenzymes CD73, CD39, and CD38 and therapeutic agents have been developed to target these as well as the downstream adenosine receptors (A₁R, A<sub>2A</sub>R, A<sub>2B</sub>R, A₃R) to enhance anti-tumor immune responses.
|
30513816 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD27 and CD40 costimulatory molecules and TILs expressing activation marker CD38 in the tumour were also correlated with patient survival.
|
26669617 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CIC-DUX4 gene fusion, resulting from either a t(4;19) or t(10;19) translocation, is the most common genetic abnormality detected in EWSR1-negative small blue round cell tumors.
|
28346326 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These nanobodies represent highly specific tools for modulating the enzymatic activity of CD38 and for diagnostic monitoring CD38-expressing tumors.
|
29084989 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Decreasing daratumumab clearance with increasing dose suggests saturation of target-mediated clearance at higher dose levels, whereas decreasing clearance over time with repeated dosing may be due to tumor burden reductions as CD38-positive cells are eliminated.
|
27896689 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reported findings of indolent presentation of MCL include: lack of B symptoms, normal serum lactic dehydrogenase (LDH) and β2-microglobulin levels (β2M), low MCL-International Prognostic Index (MIPI) score, maximum tumor diameter less than 3 cm, spleen size < 20 cm, positron emission tomography/computerized tomography with the Standard Uptake Value max <6, Ki-67 less than 30%, with some particular immunophenotype, such as CD5 and CD38 negative, markedly increased CD23 positive lymphocytes proportions, high expression of CD200, kappa light chain restriction, without C-myc, TP53 and NOTCH1/2 mutations, non-blastoid/pleomorphic histology, and no tumor growth on reevaluation every 2~3 months (followed for at least 6 months).
|
29246179 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In human xenograft MM tumor models, anti-CD38-IFNα(attenuated) exerts potent anti-tumor activity in mice, inducing complete tumor regression in most cases.
|
27611189 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Daratumumab binds a unique CD38 epitope and showed strong anti-tumor activity in preclinical models.
|
26864107 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Additionally, studies have shown that the t(X;18) translocation influences tumor behavior partly through cyclin D1 activation.
|
27334220 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD38(high) MDSCs also possess a greater capacity to suppress activated T cells, and promote tumor growth to a greater degree than CD38(low) MDSCs, likely as a result of increased iNOS production.
|
26294209 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of YWHAE-FAM22 fusion oncoproteins was demonstrated by immunoblot in t(10;17)-bearing frozen tumor and cell line samples.
|
22223660 |
2012 |